This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through November 3, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
pharmaceuticals: Archive
Top Research Reports for Broadcom, Exxon Mobil & Johnson & Johnson
by Mark Vickery
Broadcom rides surging AI semiconductor demand and VMware integration strength, even as margins tighten and debt remains a drag.
JNJPositive Net Change XOMPositive Net Change TRMBPositive Net Change AVGOPositive Net Change SYFPositive Net Change ITICPositive Net Change APTVPositive Net Change FRDPositive Net Change
industrial-products insurance oil-energy pharmaceuticals semiconductor
Can NVO Defend Its Obesity Lead as GLP-1 Competition Intensifies?
by Ahan Chakraborty
Novo Nordisk faces slowing semaglutide momentum as new obesity contenders, including GPCR's aleniglipron, push the competitive landscape forward.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence
by Kinjel Shah
Pfizer boosts its obesity ambitions by licensing YP05002, an oral GLP-1 drug now in phase I, aiming to rebuild momentum in weight-loss treatments.
PFEPositive Net Change NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change
pharmaceuticals
JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now?
by Kinjel Shah
JNJ and PFE battle patent cliffs and policy headwinds, but rising estimates and stronger 2025 momentum push JNJ ahead in this blue-chip faceoff.
JNJPositive Net Change PFEPositive Net Change
pharmaceuticals
Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal
by Aparajita Dutta
Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.
BMYPositive Net Change JNJPositive Net Change PFEPositive Net Change MRKPositive Net Change LLYPositive Net Change ABBVPositive Net Change PJPPositive Net Change IHEPositive Net Change PPHPositive Net Change
etfs pharmaceuticals
Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play
by Kinjel Shah
Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.
SNYPositive Net Change BMYPositive Net Change NVOPositive Net Change TEVAPositive Net Change
pharmaceuticals
MRK Stock Trading Above 200- & 50-Day SMA for 2 Months: Time to Buy?
by Kinjel Shah
Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
MRKPositive Net Change MRNAPositive Net Change CDTXNegative Net Change SMMTPositive Net Change
pharmaceuticals
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron
by Zacks Equity Research
Structure Therapeutics jumps after phase II data show aleniglipron delivering strong, durable weight-loss results across multiple studies.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Pharma ETF (XPH) Hits a New 52-Week High
by Sanghamitra Saha
Pharma ETF XPH hits a fresh 52-week high as healthcare shines amid AI bubble fears and slowing growth. Biotech M&A adds fuel -- can momentum hold?
XPHPositive Net Change
etfs pharmaceuticals
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Dr. Reddy's
by Zacks Equity Research
Sandoz, Teva and Dr. Reddy's emerge as standouts as generic drugmakers lean on biosimilars, complex generics and tighter cost controls.
RDYPositive Net Change TEVAPositive Net Change SDZNYPositive Net Change
pharmaceuticals
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
by Ekta Bagri
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
BIIBPositive Net Change BMYPositive Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can J&J Offset Stelara LOE, MedTech China and Legal Headwinds in 2026?
by Kinjel Shah
J&J faces Stelara losses, Medicare shifts, talc suits and China pressure, banking on new products and expects segment growth to stay on track.
JNJPositive Net Change AMGNPositive Net Change TEVAPositive Net Change
pharmaceuticals
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know
by Zacks Equity Research
Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.
ANIPPositive Net Change CRMDNegative Net Change ARQTPositive Net Change PRAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
by Zacks Equity Research
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
INCYPositive Net Change ANIPPositive Net Change CRMDNegative Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Dec 8, 2025
by Zacks Equity Research
Companies in The News Are: WBD, NFLX, MRK, VSCO, NRG
NRGPositive Net Change MRKPositive Net Change NFLXNegative Net Change WBDPositive Net Change VSCONegative Net Change
consumer-discretionary pharmaceuticals
Watch 5 Bigwigs in December After Double-Digit Returns Past Month
by Nalak Das
Five market giants, CVNA, WMT, AMAT, FCX and MRK, delivered double-digit returns last month with more room to run in December.
MRKPositive Net Change FCXPositive Net Change WMTNegative Net Change AMATPositive Net Change CVNAPositive Net Change
basic-materials internet-content pharmaceuticals retail semiconductor
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
by Zacks Equity Research
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
ANIPPositive Net Change CRMDNegative Net Change ARQTPositive Net Change ABSIPositive Net Change
biotechnology biotechs medical pharmaceuticals
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
by Zacks Equity Research
Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
ANIPPositive Net Change CRMDNegative Net Change CAPRPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals
Denali Enters Into a $275M Funding Deal With Royalty Pharma
by Ekta Bagri
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
BIIBPositive Net Change RPRXPositive Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
by Ekta Bagri
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
NVSPositive Net Change BMYPositive Net Change GILDPositive Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi
by Zacks Equity Research
Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.
SNYPositive Net Change JNJPositive Net Change LLYPositive Net Change
pharmaceuticals
LLY Trading Above 50 & 200-Day SMAs for 2 Months: How to Play the Stock
by Kinjel Shah
Lilly trades above key SMAs as strong GLP-1 demand, new drugs and pipeline momentum drive shares.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change ADVMNo Net Change
pharmaceuticals
Can Merck's New Products Aid Growth as Keytruda LOE Test Looms?
by Zacks Equity Research
MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
JNJPositive Net Change MRKPositive Net Change UTHRPositive Net Change
pharmaceuticals
BMY Gains on News of Continuation of Alzheimer's Disease Study
by Zacks Equity Research
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
BMYPositive Net Change FOLDPositive Net Change ANIPPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zoetis Stock Plummets 24.8% YTD: Here's What You Need to Know
by Zacks Equity Research
ZTS faces steep YTD losses as safety concerns hit key osteoarthritis therapies, forcing revenue cuts while new approvals aim to stabilize growth.
ZTSPositive Net Change CRMDNegative Net Change ADMAPositive Net Change ARQTPositive Net Change
biotechnology biotechs medical pharmaceuticals